$13.500
+0.964 (+7.14%)收盘时
CHRO 同业对比
In the context of the broader market, CHRO competes directly with industry leaders such as CODX and APVO. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, CHRO's gross margin of N/A stands against CODX's -48.76% and APVO's N/A. Such benchmarking helps identify whether Channel Therapeutics Corp is trading at a premium or discount relative to its financial performance.
Financials
FY2025Q1
YoY:
-5.17%
-1.83M
Operating Profit
FY2025Q1
YoY:
-23.21%
-1.97M
Net Income after Tax
FY2025Q1
YoY:
-41.82%
-0.32
EPS - Diluted
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。